PowderJect sees shares slump after losses almost double
This article was originally published in Clinica
Executive Summary
PowderJect, a UK needleless drug delivery company that has suffered a number of delays to its R&D programme for powder-delivered drugs and other molecules, announced that its losses had nearly doubled in the year to March 31. Its share price fell 13.5% to £3.80 ($6) on the news.